HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG's proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery.

Corporate Headquarters

HTG Molecular Diagnostics, Inc. (HTG)
3430 E Global Loop
Tucson, AZ 85706

HTG Mission and Cultural Beliefs

Cultural Beliefs

Icon of award winner

Customer First

Positively impact customer satisfaction daily.


Deliver Results

Deliver Results

Understand and embrace our contributions to achieving the company results.


Icon of Handshake

Practice Trust

Foster a trustful environment where open and honest feedback is valued and encouraged.


Icon of sheets of paper

Act on Facts

Make data-driven decisions and clearly communicate how and why each decision impacts the results.


Icon of signature

Take Accountability

Make commitments and take accountability for results.


Icon showing gears and a clock

Drive Process

Develop and continuously improve processes to consistently meet requirements.


Icon of a high five

Celebrate Success

Recognize individual contributions and celebrate organizational successes.



HTG's mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes.



John L. Lubniewski
President, Chief Executive Officer and Member of the Board of Directors

Shaun D. McMeans
Senior Vice President and Chief Financial Officer

Byron T. Lawson
Senior Vice President and Chief Commercial Officer

Stephen A. Barat, PhD.
Senior Vice President of Therapeutics

Laura L. Godlewski
Senior Vice President of Finance and Administration


Read Bios


Board of Directors

Ann F. Hanham, Ph.D.
Chair of the Board of Directors

Thomas (Tom) W. Dubensky

Michelle R. Griffin

Donnie (Don) M. Hardison

Christopher P. Kiritsy

John L. Lubniewski

Lee R. McCracken


Read Bios

Scientific Advisory Board

Amir Horowitz

Amir Horowitz, Ph.D.
Assistant Professor of Oncological Sciences
Precision Immunology Institute/ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai


Dr. Amir Horowitz is an Assistant Professor of Oncological Sciences and a member of the Precision Immunology Institute and the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Dr. Horowitz’s work has contributed to developing an understanding of adaptive natural killer (NK) cells and their roles in cancers, microbial infections, and following vaccination and transplantation. He pioneered the first studies of human NK cells by mass cytometry (CyTOF™) and demonstrated an enormous breadth of phenotypic diversity and functions associated with specific HLA class I and KIR backgrounds.


Mateusz Koptyra, Ph.D.
Lab Director
Center for Data Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia Research Institute
Dr. Mateusz Koptyra is Associate Technical Director at  Genomic Diagnostic Laboratory in the Center for Data Driven Discoveries in Biomedicine at Children’s Hospital of Philadelphia. He received his MS from University of Warsaw in Poland and conducted research at Temple University in Philadelphia before completing his PhD in Medical Biology at the Medical University of Warsaw. Dr. Koptyra’s work focuses on development of tumor models and molecular stratification of pediatric brain tumors with special emphasis on non-invasive diagnostics biomarker discovery


Davide Ruggero

Davide Ruggero, Ph.D.
Helen Diller Family Chair in Basic Cancer Research, UCSF
Professor, Department of Urology, UCSF


Dr. Davide Ruggero is a professor at the University of California San Francisco in the departments of Urology and Cellular and Molecular Pharmacology. Dr. Ruggero’s current research seeks to understand the molecular mechanisms by which impairments in mRNA translation, cell growth and overall protein synthesis rates lead to human disease and cancer. The implications of his research results can be applied to design a new generation of cancer therapeutic agents that modulate the cellular proteome at a post-genomic level. Dr. Ruggero has received noteworthy funding and prestigious awards in recognition of his groundbreaking cancer research.


Frank Slack


Frank Slack, Ph.D.

Director of the HMS Initiative for RNA Medicine, Beth Israel Deaconess Medical Center and the Shields Warren Mallinckrodt Professor of Medical Research, Departments of Pathology and Medicine, Harvard Medical School

Dr. Frank Slack is the Director of the HMS Institute for RNA Medicine, Beth Israel Deaconess Medical Center and the Shields Warren Mallinckrodt Professor of Medical Research, Departments of Pathology and Medicine, Harvard Medical School. He received his BSc from the University of Cape Town in South Africa before completing his Ph.D. in Molecular Biology at Tufts University School of Medicine. He began work on microRNAs as a postdoctoral fellow in Gary Ruvkun’s laboratory at Harvard Medical School, where he co-discovered the second known microRNA, let-7.


Kendall Van Keuren-JensenKendall Van Keuren-Jensen, Ph.D.
Faculty Professor, Neurogenomics Division
Professor, Department of Molecular Diagnostics and Experimental Therapeutics
Deputy Director of Research Resources
Director of Center for Noninvasive Diagnostics, TGen
Dr. Kendall Van Keuren-Jensen received her Ph.D. from Stonybrook University at the Cold Spring Harbor Laboratory in New York where she studied the role of activity-regulated genes in synaptic transmission and neuronal morphology. Following her Ph.D., Dr. Van Keuren-Jensen was a postdoctoral fellow for a short time at Harvard Medical School before coming to TGen. She also has a Master's degree in Pharmacology and Toxicology from the University of Kansas.


Page last updated August 19, 2022